Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer

(2015) Victoria Hillerdal et al.   BIODRUGS

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

TRUCKs: the fourth generation of CARs

(2015) Markus Chmielewski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

(2015) Hinrich Abken   Immunotherapy

Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy

(2015) Mahesh Jonnalagadda et al.   MOLECULAR THERAPY

The Clinical Significance of Hypoxia in Human Cancers

(2015) Neesha Dhani et al.   SEMINARS IN NUCLEAR MEDICINE

The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL

(2015) Richard Beatson et al.   PLoS One

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition

(2015) Maud Condomines et al.   PLoS One

CD28z CARs and Armored CARs

(2014) Hollie J. Pegram et al.   CANCER JOURNAL

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia

(2014) H J Pegram et al.   LEUKEMIA

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer

(2014) Elaheh Gheybi et al.   TUMOR BIOLOGY

T Cell Receptor-Engineered T Cells to Treat Solid Tumors: T Cell Processing Toward Optimal T Cell Fitness

(2014) Cor H.J. Lamers et al.   Human Gene Therapy Methods

Chimeric antigen receptor T-cell therapy for ALL

(2014) S. L. Maude et al.   Hematology-American Society of Hematology Education Program

Toxicity management for patients receiving novel T-cell engaging therapies

(2013) David M. Barrett et al.   CURRENT OPINION IN PEDIATRICS

Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia

(2013) Marco L. Davila et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

(2013) Markus Chmielewski et al.   IMMUNOLOGICAL REVIEWS

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells

(2013) Michael C. Jensen et al.   IMMUNOLOGICAL REVIEWS

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

(2013) Caroline B. Madsen et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Chimeric antigen receptor modified T cell therapy for B cell malignancies

(2013) Cameron J. Turtle   INTERNATIONAL JOURNAL OF HEMATOLOGY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

Suppression, subversion and escape: the role of regulatory T cells in cancer progression

(2012) K. Oleinika et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

(2012) D. Chinnasamy et al.   CLINICAL CANCER RESEARCH

MUC1 immunotherapy is here to stay

(2012) Takashi Kimura et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation

(2011) David M Kofler et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells

(2011) Verena Lütschg et al.   Nature Communications

MUC1 immunotherapy

(2010) Richard E Beatson et al.   Immunotherapy

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers

(2009) Nicolas Jonckheere et al.   BIOCHIMIE

CAR Mechanics: Driving T Cells into the MUC of Cancer

(2009) J. Maher et al.   CANCER RESEARCH

Strategies used for MUC1 immunotherapy: preclinical studies

(2008) Choon-Kit Tang et al.   Expert Review of Vaccines

Strategies used for MUC1 immunotherapy: human clinical studies

(2008) Choon-Kit Tang et al.   Expert Review of Vaccines